3,4-diaryl substituted isoxazole and pyrazole derivatives (Leidos)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Name3,4-diaryl substituted isoxazole and pyrazole derivatives (Leidos)
Drug Alias Name3,4-diaryl substituted isoxazole and pyrazole derivatives (SAIC-Frederick Inc)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 α mitogen-activated protein kinase stimulantsProliferation marker protein Ki-67 expression inhibitors
TargetsProliferation marker protein Ki-67P38 α mitogen-activated protein kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLeidos Biomedical Research Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLeidos Biomedical Research Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A